LRRC59

Summary

LRRC59 (leucine rich repeat containing 59, HGNC:28817) is a protein-coding gene on chromosome 17q21.33, encoding Leucine-rich repeat-containing protein 59 (Q96AG4). Required for nuclear import of FGF1, but not that of FGF2.

Enables RNA binding activity and cadherin binding activity. Predicted to be involved in intracellular signal transduction. Located in endoplasmic reticulum and mitochondrial nucleoid.

Source: NCBI Gene 55379 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 53 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018509

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28817
Approved symbol	LRRC59
Name	leucine rich repeat containing 59
Location	17q21.33
Locus type	gene with protein product
Status	Approved
Aliases	PRO1855, FLJ21675
Ensembl gene	ENSG00000108829
Ensembl biotype	protein_coding
OMIM	614854
Entrez	55379

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000225972, ENST00000503118, ENST00000576448, ENST00000894028, ENST00000894029, ENST00000894030, ENST00000894031, ENST00000927576, ENST00000927577, ENST00000927578

RefSeq mRNA: 1 — MANE Select: NM_018509 NM_018509

CCDS: CCDS11566

Canonical transcript exons

ENST00000225972 — 7 exons

Exon	Start	End
ENSE00000737040	50388060	50388132
ENSE00001018416	50392739	50392897
ENSE00001018417	50392398	50392502
ENSE00001018418	50381238	50383235
ENSE00001018419	50385118	50385291
ENSE00001018420	50394929	50394988
ENSE00002058403	50397213	50397523

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 97.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 97.6473 / max 336.7148, expressed in 1827 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166978	97.6473	1827

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	97.63	gold quality
ileal mucosa	UBERON:0000331	97.29	gold quality
body of pancreas	UBERON:0001150	97.22	gold quality
parotid gland	UBERON:0001831	97.15	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.15	gold quality
islet of Langerhans	UBERON:0000006	96.54	gold quality
pancreas	UBERON:0001264	96.52	gold quality
colonic mucosa	UBERON:0000317	96.41	gold quality
rectum	UBERON:0001052	96.40	gold quality
mucosa of transverse colon	UBERON:0004991	96.28	gold quality
right adrenal gland	UBERON:0001233	96.24	gold quality
left adrenal gland	UBERON:0001234	96.24	gold quality
right adrenal gland cortex	UBERON:0035827	96.07	gold quality
left adrenal gland cortex	UBERON:0035825	95.88	gold quality
adrenal gland	UBERON:0002369	95.71	gold quality
adrenal cortex	UBERON:0001235	95.69	gold quality
tibia	UBERON:0000979	95.03	gold quality
body of stomach	UBERON:0001161	95.03	gold quality
smooth muscle tissue	UBERON:0001135	95.00	gold quality
vermiform appendix	UBERON:0001154	94.57	gold quality
stomach	UBERON:0000945	94.23	gold quality
caecum	UBERON:0001153	93.79	gold quality
placenta	UBERON:0001987	93.70	gold quality
transverse colon	UBERON:0001157	93.65	gold quality
saliva-secreting gland	UBERON:0001044	93.64	gold quality
cartilage tissue	UBERON:0002418	93.53	gold quality
adrenal tissue	UBERON:0018303	93.50	gold quality
corpus epididymis	UBERON:0004359	93.48	gold quality
upper lobe of left lung	UBERON:0008952	93.39	gold quality
upper lobe of lung	UBERON:0008948	93.31	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-32	yes	360.89
E-HCAD-1	yes	42.93
E-MTAB-9467	yes	30.25
E-CURD-122	yes	23.50
E-ANND-3	yes	11.15

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF

miRNA regulators (miRDB)

140 targeting LRRC59, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-3663-3P	99.84	70.39	798

Literature-anchored findings (GeneRIF, showing 7)

• LRRC59 facilitates transport of cytosolic FGF1 through nuclear pores by interaction with Kpns and movement of LRRC59 along the ER and NE membranes (PMID:22321063)
• we provide a novel therapeutic mechanism for inhibiting CIP2A function in cancerous cells via targeting the CIP2A-LRRC59 interaction. (PMID:25833693)
• Endosomal localization of endogenous TLR3 was decreased by silencing of LRRC59, suggesting that LRRC59 promotes UNC93B1-mediated translocation of NA-sensing TLRs from the ER upon infection. (PMID:26466955)
• the mechanisms of membrane integration of LRRC59 and its targeting to the inner nuclear membrane (INM), were investigated. (PMID:30650545)
• LRRC59 modulates type I interferon signaling by restraining the SQSTM1/p62-mediated autophagic degradation of pattern recognition receptor DDX58/RIG-I. (PMID:31068071)
• Quantitative Proteomics Links the LRRC59 Interactome to mRNA Translation on the ER Membrane. (PMID:32788342)
• LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer. (PMID:37706625)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lrrc59	ENSMUSG00000020869
rattus_norvegicus	Lrrc59	ENSRNOG00000003524

Protein

Protein identifiers

Leucine-rich repeat-containing protein 59 — Q96AG4 (reviewed: Q96AG4)

Alternative names: Ribosome-binding protein p34

All UniProt accessions (3): Q96AG4, I3L223, I3L2E8

UniProt curated annotations — full annotation on UniProt →

Function. Required for nuclear import of FGF1, but not that of FGF2. Might regulate nuclear import of exogenous FGF1 by facilitating interaction with the nuclear import machinery and by transporting cytosolic FGF1 to, and possibly through, the nuclear pores.

Subunit / interactions. Can form homodimers. Interacts with SGO1. Interacts with FGF1.

Subcellular location. Microsome membrane. Endoplasmic reticulum membrane. Nucleus envelope.

Tissue specificity. Widely expressed.

RefSeq proteins (1): NP_060979* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050216	LRR_domain-containing	Family

Pfam: PF00560, PF13855

UniProt features (21 total): modified residue 6, repeat 5, chain 2, compositionally biased region 2, topological domain 2, initiator methionine 1, region of interest 1, coiled-coil region 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96AG4-F1	87.90	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 1, 2, 23, 25, 73, 135

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 230 (showing top): ELVIDGE_HYPOXIA_DN, TTTGTAG_MIR520D, GOLDRATH_ANTIGEN_RESPONSE, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, NF1_Q6_01, TGGNNNNNNKCCAR_UNKNOWN, CTTTGTA_MIR524, ACEVEDO_LIVER_CANCER_UP, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, BERENJENO_TRANSFORMED_BY_RHOA_UP, AGCATTA_MIR155, GOCC_NUCLEAR_ENVELOPE, GOCC_NUCLEOID

GO Biological Process (1): intracellular signal transduction (GO:0035556)

GO Molecular Function (3): RNA binding (GO:0003723), cadherin binding (GO:0045296), protein binding (GO:0005515)

GO Cellular Component (7): nuclear envelope (GO:0005635), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), mitochondrial nucleoid (GO:0042645), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	2
endomembrane system	2
cellular anatomical structure	2
intracellular membrane-bounded organelle	2
signal transduction	1
nucleic acid binding	1
cell adhesion molecule binding	1
binding	1
nucleus	1
organelle envelope	1
cytoplasm	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
mitochondrion	1
mitochondrial matrix	1
nucleoid	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

2200 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRC59	UBXN4	Q92575	579
LRRC59	FGF1	P05230	564
LRRC59	LRRC25	Q8N386	476
LRRC59	ANAPC5	Q9UJX4	460
LRRC59	ITPKC	Q96DU7	448
LRRC59	RASSF4	Q9H2L5	446
LRRC59	TRMT11	Q7Z4G4	445
LRRC59	MACIR	Q96GV9	438
LRRC59	EPRS1	P07814	424
LRRC59	TMEM135	Q86UB9	419
LRRC59	DEUP1	Q05D60	418
LRRC59	SEC62	Q99442	411
LRRC59	HM13	Q8TCT9	410
LRRC59	A0A087WVV2	A0A087WVV2	384
LRRC59	PLPBP	O94903	375

IntAct

254 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
ASPH	STXBP3	psi-mi:“MI:0914”(association)	0.640
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
TMBIM6	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
LRRC59	TMEM60	psi-mi:“MI:0915”(physical association)	0.560
LRRC59	TMEM222	psi-mi:“MI:0915”(physical association)	0.560
LRRC59	CMTM3	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
EDDM3B	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
EBP	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
TSPO2	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
CNIH1	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
TMEM97	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
AGTRAP	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
LRRC59	CMTM5	psi-mi:“MI:0915”(physical association)	0.560
LRRC59	NDRG4	psi-mi:“MI:0915”(physical association)	0.560
TRAM1L1	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
AQP1	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
SNORC	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
MTNR1A	PGRMC1	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
ESR2	FBLL1	psi-mi:“MI:0914”(association)	0.460
MAP4K4	LRRC59	psi-mi:“MI:0915”(physical association)	0.400
REEP5	LRRC59	psi-mi:“MI:0915”(physical association)	0.400
ZSCAN21	LRRC59	psi-mi:“MI:0915”(physical association)	0.400
RSL1D1	LRRC59	psi-mi:“MI:0915”(physical association)	0.400
RPL8	LRRC59	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (1050): LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Co-fractionation), LRRC59 (Affinity Capture-MS), LRRC59 (Affinity Capture-MS), LRRC59 (Proximity Label-MS), LRRC59 (Proximity Label-MS), LRRC59 (Proximity Label-MS)

ESM2 similar proteins: A1YVX4, A5D989, A8IF44, A8J637, A8JBB2, A9UQM0, B4PYR0, D4P3R7, O01615, O60341, O97628, P09661, P29692, P41229, P41230, P53787, P53904, P55201, P57784, Q09JZ4, Q38JA7, Q4R3D4, Q4R8Y8, Q5BFH3, Q5E9X4, Q5M7N8, Q5RJR8, Q6C4F8, Q6FV04, Q6MG08, Q6NX28, Q6P4W5, Q6P542, Q6ZQ88, Q755D2, Q767L0, Q7JVP4, Q7K2B0, Q7SIA2, Q7YR37

Diamond homologs: Q5E9X4, Q5F334, Q5RJR8, Q6NWG1, Q6NX28, Q8AVS8, Q922Q8, Q96AG4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 207 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
VEGFR2 mediated cell proliferation	5	21.8×	2e-04
RAF activation	7	17.9×	6e-05
Signaling by high-kinase activity BRAF mutants	7	16.9×	6e-05
MAP2K and MAPK activation	7	15.3×	8e-05
Signaling by RAF1 mutants	7	14.9×	8e-05
Downstream signal transduction	5	14.5×	1e-03
Signaling by moderate kinase activity BRAF mutants	7	13.6×	8e-05
Paradoxical activation of RAF signaling by kinase inactive BRAF	7	13.6×	8e-05

GO biological processes:

GO term	Partners	Fold	FDR
MAPK cascade	10	8.4×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2332 predictions. Top by Δscore:

Variant	Effect	Δscore
17:50378581:G:A	acceptor_gain	1.0000
17:50378675:A:T	donor_gain	1.0000
17:50378773:GGGA:G	acceptor_gain	1.0000
17:50378851:G:T	donor_gain	1.0000
17:50378852:A:T	donor_gain	1.0000
17:50379450:A:AG	acceptor_gain	1.0000
17:50379451:G:GA	acceptor_loss	1.0000
17:50379451:G:GG	acceptor_gain	1.0000
17:50379565:CAAGT:C	donor_loss	1.0000
17:50379566:AAGT:A	donor_loss	1.0000
17:50379567:AGTG:A	donor_loss	1.0000
17:50379568:G:GG	donor_gain	1.0000
17:50379569:T:A	donor_loss	1.0000
17:50379570:GAGT:G	donor_loss	1.0000
17:50379571:AGTAA:A	donor_loss	1.0000
17:50383236:C:CC	acceptor_gain	1.0000
17:50385114:TTACT:T	donor_loss	1.0000
17:50385115:TACTC:T	donor_loss	1.0000
17:50385116:A:AC	donor_gain	1.0000
17:50385116:A:T	donor_loss	1.0000
17:50385116:ACT:A	donor_gain	1.0000
17:50385117:C:CA	donor_gain	1.0000
17:50385117:CT:C	donor_gain	1.0000
17:50385117:CTC:C	donor_gain	1.0000
17:50385117:CTCG:C	donor_gain	1.0000
17:50385117:CTCGG:C	donor_gain	1.0000
17:50385135:T:TA	donor_gain	1.0000
17:50385287:TGCCT:T	acceptor_gain	1.0000
17:50385288:GCCT:G	acceptor_gain	1.0000
17:50385289:CCTC:C	acceptor_gain	1.0000

AlphaMissense

1981 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:50392788:A:G	L92P	1.000
17:50392489:A:G	L113S	0.999
17:50392493:A:G	W112R	0.999
17:50392493:A:T	W112R	0.999
17:50392788:A:T	L92H	0.999
17:50392847:G:C	N72K	0.999
17:50392847:G:T	N72K	0.999
17:50392857:A:G	L69P	0.999
17:50394957:A:G	L46P	0.999
17:50392434:G:C	C131W	0.998
17:50392436:A:G	C131R	0.998
17:50392473:G:C	N118K	0.998
17:50392473:G:T	N118K	0.998
17:50392483:A:G	L115P	0.998
17:50392491:C:A	W112C	0.998
17:50392491:C:G	W112C	0.998
17:50392778:G:C	N95K	0.998
17:50392778:G:T	N95K	0.998
17:50392794:A:G	L90P	0.998
17:50392803:A:T	L87H	0.998
17:50392848:T:A	N72I	0.998
17:50392857:A:T	L69Q	0.998
17:50392863:A:G	L67P	0.998
17:50394947:A:C	N49K	0.998
17:50394947:A:T	N49K	0.998
17:50397253:A:G	L22P	0.998
17:50397259:A:G	L20P	0.998
17:50392417:C:G	C137S	0.997
17:50392418:A:G	C137R	0.997
17:50392418:A:T	C137S	0.997

dbSNP variants (sampled 300 via entrez): RS1000052774 (17:50399329 G>A), RS1000181009 (17:50381074 AT>A), RS1000191765 (17:50392318 T>G), RS1000348358 (17:50386512 T>C), RS1000395419 (17:50386105 G>A), RS1000517690 (17:50397508 C>A,G), RS1000526136 (17:50390758 G>A), RS1000592061 (17:50399019 G>A,T), RS1000657417 (17:50381304 G>C), RS1001135661 (17:50384696 C>G,T), RS1001287298 (17:50385619 A>G), RS1001351859 (17:50392135 G>A), RS1001657631 (17:50392132 G>A), RS1001704756 (17:50398265 C>A,G,T), RS1001735397 (17:50391945 T>C)

Disease associations

OMIM: gene MIM:614854 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2216743 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.09	Kd	8.2	nM	CHEMBL5653589
8.09	ED50	8.2	nM	CHEMBL5653589
6.79	Kd	163.1	nM	CHEMBL3752910
6.79	ED50	163.1	nM	CHEMBL3752910
5.00	IC50	1e+04	nM	MOLIBRESIB

PubChem BioAssay actives

3 with measured affinity, of 13 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148667: Binding affinity to human LRRC59 incubated for 45 mins by Kinobead based pull down assay	kd	0.0082	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148667: Binding affinity to human LRRC59 incubated for 45 mins by Kinobead based pull down assay	kd	0.1631	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179017: Inhibition of LRRC59 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	10.0000	uM

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression	3
Tobacco Smoke Pollution	affects expression, increases expression	3
Cadmium Chloride	decreases reaction, increases abundance, increases palmitoylation, increases expression	3
sodium arsenite	increases expression	2
Cadmium	increases expression, decreases reaction, increases abundance, increases palmitoylation	2
Nickel	increases expression	2
FR900359	decreases phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	increases expression	1
lead acetate	increases expression	1
sodium arsenate	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
methylparaben	increases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
4-hydroxy-2-nonenal	affects binding	1
cupric chloride	increases expression	1
cupric oxide	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
LDN 193189	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2217170	Binding	Binding affinity to LRC59 in human HepG2 cell lysate after 1 hr by capture compound based LC/MS analysis	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). — J Med Chem

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3AB	Abcam HEK293T LRRC59 KO	Transformed cell line	Female
CVCL_D8PG	Ubigene HCT 116 LRRC59 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.